We are live on ! Find out more
KCM

Kynam Capital Management Portfolio holdings

AUM $1.62B
1-Year Est. Return 138.67%
This Fund
S&P 500
This Quarter Est. Return
+9.14%
1 Year Est. Return
+138.67%
3 Year Est. Return
+268.43%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$727M
AUM Growth
-$47.6M
Cap. Flow
-$46.8M
Cap. Flow %
-6.44%
Top 10 Hldgs %
82.71%
Holding
37
New
2
Increased
11
Reduced
6
Closed
11

Top Buys

Rank Stock Value
1
CLDX icon
Celldex Therapeutics
CLDX
+$40.1M
2
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$14.8M
3
COGT icon
Cogent Biosciences
COGT
+$14M
4
TSVT
2seventy bio
TSVT
+$12.2M
5
VRDN icon
Viridian Therapeutics
VRDN
+$4.26M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$119M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$20.2M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$18.6M
4
GSK icon
GSK
GSK
+$17.7M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 89.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GYRE icon
26
Gyre Therapeutics
GYRE
$662M
$31.6K ﹤0.01%
5,992
– –
ACLX
27
DELISTED
Arcellx
ACLX
– –
-31,336
Closed -$965K
ALLO icon
28
Allogene Therapeutics
ALLO
$601M
– –
-1,495,981
Closed -$7.39M
GOSS icon
29
Gossamer Bio
GOSS
$66.5M
– –
-1,502,866
Closed -$1.89M
GSK icon
30
GSK
GSK
$103B
– –
-498,329
Closed -$17.7M
IOVA icon
31
Iovance Biotherapeutics
IOVA
$2.23B
– –
-1,800,000
Closed -$11M
MCRB icon
32
Seres Therapeutics
MCRB
$48M
– –
-38,446
Closed -$4.36M
MRUS
33
DELISTED
Merus
MRUS
– –
-21,457
Closed -$395K
XENE icon
34
Xenon Pharmaceuticals
XENE
$6.32B
– –
-28,696
Closed -$1.03M
MRTX
35
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-499,853
Closed -$18.6M
SGEN
36
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-100,000
Closed -$20.2M
HZNP
37
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-1,094,620
Closed -$119M
1
2

Similar funds

IPW
Invictus Private Wealth Denver, Colorado $1.62B AUM 22.63% 1-Year Est. Return
WIC
Woodmont Investment Counsel Nashville, Tennessee $1.62B AUM 18.92% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
TLFA
True Link Financial Advisors San Francisco, California $1.62B AUM 8.33% 1-Year Est. Return
KCM
Kathmere Capital Management Wayne, Pennsylvania $1.62B AUM 17.7% 1-Year Est. Return
PRA
Pine Ridge Advisers New York $1.62B AUM 16.97% 1-Year Est. Return
BW
Browning West Los Angeles, California $1.62B AUM 22.28% 1-Year Est. Return
CC
Covalis Capital London, United Kingdom $1.63B AUM 27.84% 1-Year Est. Return

Kynam Capital Management's Q2 2023 Portfolio in Review

As of Q2 2023, Kynam Capital Management held 37 positions worth $727M, down 6.1% from $775M the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Kynam Capital Management withdrew a net $46.8M in Q2 2023, closing 11 positions and reducing 6 holdings. Its most notable exit was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $119M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 100% a quarter earlier.

Against the trend, Kynam Capital Management added an estimated $40.1M to Celldex Therapeutics.

  • Kynam Capital Management added most to Celldex Therapeutics in Q2 2023, an estimated $40.1M increase.
  • Kynam Capital Management's biggest Q2 2023 reduction was Protagonist Therapeutics, cutting an estimated $10M.
  • Kynam Capital Management fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2023, selling an estimated $119M.
  • Kynam Capital Management's ten largest holdings make up 83% of its $727M portfolio in Q2 2023.
  • Kynam Capital Management opened 2 new positions and closed 11 in Q2 2023.
  • Kynam Capital Management's portfolio value fell 6.1% quarter-over-quarter to $727M.

Based on Kynam Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.